Table 3 Characteristics of patients in TCGA cohorts

Age at initial pathologic diagnosis (median, range)

58 (26–90)

66 (33–88)

61 (41–77)

Sex (male), n (%)

10 (1.1%)

191 (44.8%)

392 (100%)

American Joint Committee on Cancer (AJCC) tumor stage (n)

Stage I: 77

Stage IA: 76

Stage IB: 5

Stage II: 6

Stage IIA: 286

Stage IIB: 207

Stage III: 2

Stage IIIA: 128

Stage IIIB: 18

Stage IIIC: 51

Stage IV: 13

Unknown: 17

Stage I: 5

Stage IA: 122

Stage IB: 108

Stage II: 1

Stage IIA: 47

Stage IIB: 58

Stage IIIA: 50

Stage IIIB: 5

Stage IV: 22

Unknown: 8

Unknown: 392 (100%)

Whole genome doublings (WGD)

0: 435, 56.8%

1: 298, 38.5%

2: 37, 4.8%

Unknown: 116

0: 168, 41.9%

1: 193, 48.1%

2: 40, 10.0%

Unknown: 25

0: 337, 92.1%

1: 29, 7.9%

Unknown: 26

Progression-free survival (PFS, median)

122.3 months

29.3 months

116.7 months

Overall survival (OS, median)

131.4 months

48.5 months

Not reached